BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
      • Artificial intelligence
    • Coronavirus
    • Israel
    • IVDs on the rise
    • Radiopharmaceuticals
    • Rise of obesity
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 10, 2023
Home » Topics » Clinical

Clinical
Clinical RSS Feed RSS

Janssen’s vaccine candidate

J&J pauses COVID-19 vaccine trial after unexplained illness

Oct. 13, 2020
By Michael Fitzhugh
No Comments
Johnson & Johnson said it has temporarily paused further dosing of its adenoviral vector-based COVID-19 vaccine candidate, JNJ-78436735, due to an unexplained illness in a study participant. Trial enrollment is also on hold while the company awaits a recommendation on how to proceed from the study's data safety monitoring board.
Read More

NIH trial testing Lilly antibody against COVID-19 paused

Oct. 13, 2020
By Michael Fitzhugh
No Comments
An NIH-sponsored phase III trial testing Eli Lilly and Co.'s SARS-CoV-2 neutralizing antibody candidate, LY-CoV555, alongside the Gilead Sciences Inc. antiviral Veklury (remdesivir) has been paused at the request of its data safety monitoring board, the company told BioWorld.
Read More
Coronavirus, lungs

Apogenix adds cancer drug asunercept to COVID-19 fight; phase II study underway

Oct. 13, 2020
By Nuala Moran
No Comments
LONDON – Apogenix GmbH has added its CD95 ligand inhibitor, asunercept, to the band of cancer immunotherapies that are being repurposed to treat the most severe effects of COVID-19 infection.
Read More

In the clinic for Oct. 13, 2020

Oct. 13, 2020
No Comments
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Algernon, Boehringer, Cytrx, Evelo, Gossamer, Humanigen, J&J, Lineage Cell, Mesoblast, Moleculin, Nabriva, Nanobiotix, Nasus, Neurorx, Regeneron, Relief, Sanofi, Targovax, Uniqure, Vaxart.
Read More

In the clinic for Oct. 12, 2020

Oct. 12, 2020
No Comments
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Amicus, Amylyx, Astellas, Astrazeneca, Basilea, BMS, Celltrion, Galapagos, Gilead, Gossamer, Janssen, Kuur, Lilly, Rhovac, Seagen, Seres, Takeda, Vedanta.
Read More

J&J pauses COVID-19 vaccine trial after unexplained illness

Oct. 12, 2020
By Michael Fitzhugh
No Comments

Sobi's avatrombopag falls short in phase III chemotherapy-induced thrombocytopenia trial

Oct. 9, 2020
By Michael Fitzhugh
No Comments
A phase III failure of Swedish Orphan Biovitrum AB's oral thrombopoietin receptor agonist avatrombopag to effectively outperform a placebo in treating chemotherapy-induced thrombocytopenia, or low platelet counts, sent company shares down 17.9% on Oct. 9.
Read More
Health professional holding stethoscope with health icons

After a slow summer, clinical trial reports pick up in September

Oct. 9, 2020
By Karen Carey
No Comments
As clinical trials, halted due to the COVID-19 pandemic, begin to resume and biopharma companies find workarounds to keep the research going, activity in phase I, II and III studies picked up by more than 40% in September.
Read More

In the clinic for Oct. 9, 2020

Oct. 9, 2020
No Comments
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Apellis, Bold, Caladrius, CSL, Emergent, Gilead, Grifols, Pfizer, Rigel, Sobi, Sumitomo Dainippon, Takeda, University of Oxford.
Read More
Heart illustration

First patients treated in study of Centauri pulsed electric field cardiac ablation system

Oct. 8, 2020
By Liz Hollis
No Comments
San Carlos, Calif.-based Galaxy Medical Inc., which has developed pulsed electric field (PEF) technology for the treatment of cardiac arrhythmias, revealed the first treatments in the ECLIPSE-AF study, which is evaluating the Centauri system. The trial will assess the safety and efficacy of the Centauri as the company looks forward to obtaining a CE mark.
Read More
Previous 1 2 … 222 223 224 225 226 227 228 229 230 … 307 308 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 8, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for December 8, 2023.
  • Stock chart with falling red arrow

    ‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

    BioWorld
    For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...
  • Coronavirus, mRNA and syringe

    Off-target immune response from modified mRNA impacts future development

    BioWorld
    The Nobel Prize-winning modification that prevents the innate immune system from recognizing injected mRNA as foreign and blocking transcription of the protein it...
  • Feet and scale

    Waging the losing battle: Altimmune takes on challengers as Pfizer falls back

    BioWorld
    Altimmune Inc.’s peptide-based glucagon-like peptide-1/glucagon dual receptor agonist pemvidutide hiccupped in a phase I study earlier this year but has bounced...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing